Tempest Therapeutics Plunges 14.19% After ATM Program Termination

On June 11, 2025, Tempest Therapeutics experienced a significant drop of 14.19% in pre-market trading, marking a notable decline in its stock performance.

Tempest Therapeutics, a pharmaceutical company, announced the termination of its automatic teller machine (ATM) prospectus with Jefferies. This decision was formally communicated through a written notice delivered to Jefferies, indicating the company's intention to suspend and terminate the ATM program. The move suggests a strategic shift in the company's financial management, potentially impacting investor confidence and market perception.

On the same day, Tempest Therapeutics filed a Form 8-K with the Securities and Exchange Commission, detailing the termination of the ATM program. This filing provides transparency into the company's decision-making process and its compliance with regulatory requirements. The termination of the ATM program may signal a change in the company's capital-raising strategy, which could influence its future financial performance and stock valuation.